{"product_id":"astrazeneca-swot-analysis","title":"AstraZeneca SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAstraZeneca’s robust R\u0026amp;D pipeline and strong oncology portfolio position it well for sustained growth, but pricing pressure and regulatory risks could temper upside; strategic partnerships and emerging-market expansion offer clear opportunities. Discover the full SWOT analysis to get detailed, research-backed insights, editable Word and Excel deliverables, and actionable recommendations crafted for investors, consultants, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Oncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstraZeneca’s oncology portfolio, anchored by Tagrisso (osimertinib), Enhertu (trastuzumab deruxtecan), and Imfinzi (durvalumab), generated ~£14.5bn in 2024 oncology revenue, up 18% YoY, driven by expanded indications and ADC (antibody-drug conjugate) uptake.\u003c\/p\u003e\n\u003cp\u003eHigh-margin oncology sales now account for ~45% of group product revenue, providing predictable cash flow and funding R\u0026amp;D pipelines targeting 2026 readouts for multiple ADC and targeted-therapy trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Rare Disease Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Alexion acquisition (closed July 2021) has shifted AstraZeneca’s mix: rare-disease sales grew to about $6.4bn in 2024, adding higher-margin, long-patent biologics that dilute reliance on primary care and oncology revenues.\u003c\/p\u003e\n\u003cp\u003eRare-disease drugs face limited competition and average patent lifetimes of 10+ years, giving AstraZeneca a steady high-price revenue stream that acted as a defensive buffer during the 2023–24 macro slowdown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Presence in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAstraZeneca has one of the strongest commercial footprints in emerging markets, notably China where sales rose 18% to $7.1bn in 2024, outpacing many peers. This deep infrastructure captures demand as middle-class healthcare spending expands, driving double-digit volume growth in ASEAN and LATAM. Emerging markets now supply roughly 30% of group revenue, helping offset low-single-digit growth in mature Western markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Late-Stage Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAstraZeneca enters 2026 with 28 Phase III trials and five expected major regulatory readouts in 2026, sustaining product launch cadence to offset patents on Symbicort and Tagrisso.\u003c\/p\u003e\n\u003cp\u003eThis late-stage density boosts revenue visibility: management projects 2026–2028 incremental peak sales of $12–15 billion from late-stage assets, supporting free cash flow recovery and dividend coverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28 Phase III trials (start of 2026)\u003c\/li\u003e\n\u003cli\u003e5 major readouts expected in 2026\u003c\/li\u003e\n\u003cli\u003eProjected $12–15bn peak sales from pipeline (2026–28)\u003c\/li\u003e\n\u003cli\u003eHelps replace revenues from Symbicort\/Tagrisso patent cliffs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Innovation Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAstraZeneca leverages strategic partnerships and licensing to extend R\u0026amp;D capacity; in 2024 it reported 35 active collaborations in biologics and gene therapy, reducing upfront spend by an estimated $1.1bn vs solo development.\u003c\/p\u003e\n\u003cp\u003eWorking with biotech and universities lets AZ share risk and upside for cell and gene modalities, accelerating 12+ preclinical-to-clinic programs since 2022 while keeping fixed R\u0026amp;D outlays relatively stable at ~£6.0bn in 2024.\u003c\/p\u003e\n\u003cp\u003eThat flexible model preserves capital, speeds time-to-clinic, and sustains pipeline breadth without full early-stage cost exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35 active collaborations (2024)\u003c\/li\u003e\n\u003cli\u003e$1.1bn estimated savings vs solo R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003e12+ cell\/gene programs advanced since 2022\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend ~£6.0bn (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology-led growth: £14.5bn 2024 sales, $6.4bn Alexion, $12–15bn peak potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrong oncology franchise (Tagrisso, Enhertu, Imfinzi) drove ~£14.5bn oncology sales in 2024 (+18% YoY), high-margin products ~45% of group revenue, Alexion added ~$6.4bn rare-disease sales, emerging markets ~30% of revenue ($7.1bn China), 28 Phase III trials with 5 major 2026 readouts and projected $12–15bn peak sales from late-stage assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology sales\u003c\/td\u003e\n\u003ctd\u003e£14.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology % of product rev\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlexion\/rare-disease sales\u003c\/td\u003e\n\u003ctd\u003e$6.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina sales\u003c\/td\u003e\n\u003ctd\u003e$7.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets % revenue\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase III trials (start 2026)\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2026 readouts\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected peak sales (2026–28)\u003c\/td\u003e\n\u003ctd\u003e$12–15bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT assessment of AstraZeneca, highlighting its R\u0026amp;D-led strengths, portfolio and pipeline opportunities, operational and regulatory weaknesses, and external market and competitive threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise AstraZeneca SWOT matrix for fast, visual strategy alignment and quick stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Debt Levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpastrazeneca acquisition of alexion for billion dollars and other deals pushed net debt to about by end-2023 leaving significant leverage on the balance sheet. while operating cash flow reached roughly in a large share is earmarked interest servicing constraining free uses. this high load reduces financial flexibility likely limits firm ability pursue further billion-dollar m near term.\u003e\n\u003c\/pastrazeneca\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpastrazeneca derives roughly of revenue from top five drugs led by oncology tagrisso and immuno-oncology imfinzi cvrm farxiga any regulatory action or trial failure could cut eps sharply trigger\u003e10% intraday stock drops seen after past safety scares.\n\u003c\/pastrazeneca\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging AstraZeneca’s global supply chain and 70,000-strong workforce across oncology, CVRM, respiratory and rare diseases raises heavy admin and operational burdens, driving SG\u0026amp;A pressure—2024 operating expenses were $18.3B. Manufacturing advanced biologics and cell therapies needs specialized plants and experts, lifting fixed costs and capital spend—capital expenditures hit $5.1B in 2024. Any disruption can cause shortages and share loss in fast-growing oncology markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Litigation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAstraZeneca faces ongoing patent disputes and product-liability suits common to big pharma; in 2024 legal provisions rose to $1.2bn, reflecting higher case exposure and reserve build-ups.\u003c\/p\u003e\n\u003cp\u003eDefending cases consumes major legal spend and can force settlements or loss of exclusivity on drugs that generated multibillion-dollar peak sales (eg, blockbusters with \u0026gt;$1bn annual sales), creating shareholder risk.\u003c\/p\u003e\n\u003cp\u003eLegal uncertainty also diverts senior management time from R\u0026amp;D and commercial strategy, raising execution risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 legal provisions: $1.2bn\u003c\/li\u003e\n\u003cli\u003ePotential blockbuster at-risk sales: \u0026gt;$1bn\/year\u003c\/li\u003e\n\u003cli\u003eOutcome variance: settlement vs. exclusivity loss\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpastrazeneca spent billion usd on r in keeping its ratio near among the industry highest that sustains pipeline growth but compresses operating margins versus peers with lower ratios.\u003e\n\u003cpif clinical-to-approval conversion slows roic could fall sharply given hefty upfront costs and long lead times attrition would magnify margin pressure cash strain.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D spend: 7.0 bn USD\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D\/revenue ~21% in 2024\u003c\/li\u003e\n\u003cli\u003eHigh ratio reduces operating margin vs peers\u003c\/li\u003e\n\u003cli\u003eLower trial conversion → significantly weaker ROIC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pif\u003e\u003c\/pastrazeneca\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca: Heavy Debt, Concentrated Drug Risk and Cost Pressures Threaten Flexibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpastrazeneca high leverage debt with heavy interest service despite operating cash flow m and flexibility top-five drugs drive of revenue concentrating regulatory trial risk r spend capex squeeze margins legal provisions raise litigation exclusivity risks.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (end-2023)\u003c\/td\u003e\n\u003ctd\u003e$33.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp cash flow (2024)\u003c\/td\u003e\n\u003ctd\u003e$19B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$7.0B (21% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex (2024)\u003c\/td\u003e\n\u003ctd\u003e$5.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal provisions (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pastrazeneca\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAstraZeneca SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752470196601,"sku":"astrazeneca-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/astrazeneca-swot-analysis.png?v=1772241376","url":"https:\/\/matrixbcg.com\/products\/astrazeneca-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}